Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab in hepatocellular carcinoma
TACE plus sintilimab-bevacizumab biosimilar has favorable efficacy and manageable safety in patients with uHCC, supporting its use as a treatment option in HCC.
Authors
- Yunfei Tian (ORCID: https://orcid.org/0009-0001-3532-6399)
- Yi Wu
- Tonggang Zhou (ORCID: https://orcid.org/0009-0003-4205-1527)
- Yusheng Song
Institutions
- Ganzhou People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fonc.2025.1739249
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China